Company Overview
Company Type: Public Company
Website: www.theratech.com
Number of Employees: 144
Ticker: TH (TSX)
Year Founded: 1993


Business Description
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
108.4
Market Capitalization
61.8
TEV/Total Revenue
1.0x
EBITDA
(11.7)
Total Enterprise Value
109.6
TEV/EBITDA
NM
EBIT
(16.2)
Cash & ST Invst.
31.1
P/Diluted EPS Before Extra
NM
Net Income
(39.6)
Total Debt
79.2
Price/Tang BV
NM
Capital Expenditure
(0.5)
Total Assets
77.1
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Aug-31-2023 TEV and Market Cap are calculated using a close price as of Oct-10-2023


Estimates & Guidance Snapshot (Current Fiscal Year End: Nov-30-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Guidance Current FQ
Current FY
Guidance Current FY
NTM
EPS Normalized
(0.62)
-
(1.25)
-
(0.57)
Revenue (mm)
32.98
-
112.89
110.46 - 114.50
129.38
EBITDA (mm)
2.79
-
(7.76)
0.00 - -
5.71

Forward Multiples (Current FY)

Price/Earnings
NM
TEV/REV
0.95x
TEV/EBITDA
NM
P/BV
NM

Non-Periodic Estimates

Recommendation
Outperform (2.00)
Target Price
6.75
Potential Upside
175.51%


Key Professionals
Name
Title
Lévesque, Paul 
President, CEO & Director
Dubuc, Philippe 
Senior VP & CFO
Lafond, Jocelyn 
General Counsel & Corporate Secretary
Dupras, Andre 
Vice President of Human Resources
Marsolais, Christian 
Senior VP & Chief Medical Officer
Leasure, John 
Global Commercial Officer

Key Board Members
Name
Title
Svoronos, Dawn A.
Independent Chair of the Board
Lévesque, Paul 
President, CEO & Director
Lacoste, Gerald A.
Independent Director
MacCandlish-Weil, Dale 
Independent Director
Trudeau, Alain 
Independent Director
Arena, Joseph P.
Independent Director
Clemmons, David 
Member of the Scientific Advisory Board
Falutz, Julian
Member of the Scientific Advisory Board
Grinspoon, Steven
Member of the Scientific Advisory Board
Guillemin, Roger 
Member of the Scientific Advisory Board
Holler, Frank A.
Independent Director
Merriam, George R.
Member of the Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
2015 Peel Street 11th Floor | Montreal, QC | H3A 1T8 | Canada
Phone: 514 336 7800   Fax: 514 331 9691

Current and Pending Investors
Fonds de solidarité FTQ, Merck KGaA (XTRA:MRK), Scotia Asset Management L.P., Societe d'Investissements en Participations Inc.

Prior Investors
Dynamic Qssp Fund, Natcan Investment Management Inc., Societe Generale de Financement du Quebec, T2C2 Capital, T2C2/Bio, L.P.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 2.45
Market Cap (mm)
59.3
Open
 2.51
Shares Out. (mm)
24.2
Previous Close
 2.45
Float %
89.5%
Change on Day
(0.10)
Shares Sold Short (mm)
-
Change % on Day
(3.9)%
Dividend Yield %
-
Day High/Low
 2.55/ 2.42
Diluted EPS Excl. Extra Items
(1.64)
52 wk High/Low
 12.20/ 1.22
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0079
Avg 3M Dly Vlm (mm)
0.09
Beta 5Y
1.15


 
Delayed Quote** | Last Updated on Oct-11-2023 12:00 AM (GMT-5)
TSX:TH - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Katana Biopharma Inc.
Katana Biopharma Inc., a biotech company, engages in the development of targeted oncology drugs. It develops technology platform using peptides as a vehicle to deliver cytotoxic agents to cancer cells via the targeting of sortilin receptors. The company was founded in 2016 and is based in Montreal, Canada. As of February 25, 2019, Katana Biopharma Inc. operates as a subsidiary of Theratechnologies Inc.

United States and Canada
Pharmaceuticals
-
-
-
PharamG
PharmaG researches and develops the technology needed to improve illnesses that affect women including dysmenorrhea (pre-menstrual cramps), premature labor and osteoporosis.

United States and Canada
Pharmaceuticals
-
-
-
Pharma-G Inc.
As of September 26, 2000, Pharma-G Inc. was acquired by Theratechnologies Inc. Pharma-G Inc. is a proteomics pharmaceutical company that researches and develops therapeutic peptide compounds. The company is based in Quebec, Canada.

United States and Canada
Biotechnology
-
-
-
Theratechnologies Canada Inc

United States and Canada
-
-
-
-
Theratechnologies Europe Inc

United States and Canada
-
-
-
-
Theratechnologies Europe Limited
Theratechnologies Europe Limited manufactures pharmaceutical products. The company was incorporated in 2017 and is based in Dublin 2Dublin, Ireland.

Europe
Pharmaceuticals
-
-
-
Theratechnologies Me Inc

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Nov-22-2021
-
Shelf Registration
Target
Theratechnologies Inc. (TSX:TH)


150.00
Jul-23-2021
-
Public Offering
Target
Theratechnologies Inc. (TSX:TH)


50.00
Jan-11-2021
Jan-19-2021
Public Offering
Target
Theratechnologies Inc. (TSX:TH)


40.00
Oct-11-2019
-
Shelf Registration
Target
Theratechnologies Inc. (TSX:TH)


150.00
Feb-25-2019
Feb-25-2019
Merger/Acquisition
Buyer
Katana Biopharma Inc.
Theratechnologies Inc. (TSX:TH)

5.27
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-04-2023
Product-Related Announcements
Theratechnologies Inc. Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA
Sep-27-2023
Company Conference Presentations
Theratechnologies Inc. Presents at Cantor Fitzgerald Annual Global Healthcare Conference 2023, Sep-27-2023 08:00 AM
Sep-26-2023
Earnings Calls
Theratechnologies Inc., Q3 2023 Earnings Call, Sep 26, 2023
Sep-25-2023
Debt Financing Related
Theratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan Facility
Sep-25-2023
Product-Related Announcements
Theratechnologies Submits Tesamorelin F8 Formulation Sbla for Fda Review

Competitors
Bristol-Myers Squibb Company (NYSE:BMY), Gilead Sciences, Inc. (NasdaqGS:GILD), GSK plc (LSE:GSK), Janssen Therapeutics, Johnson & Johnson (NYSE:JNJ), Merck Sharp & Dohme LLC, Pfizer Limited (NSEI:PFIZER), Sanofi Pasteur Inc.


Advisors
Most Recent Auditor
KPMG Limited
Private Placement Advisors
BMO Capital Markets Corp., Fasken Martineau DuMoulin LLP, Kirkland & Ellis LLP, Lazard Ltd (NYSE:LAZ)
Public Offering Advisors
Fasken Martineau DuMoulin LLP, Goodwin Procter LLP, Jenner & Block LLP, KPMG LLP (Canada)
Key development Advisor
BMO Capital Markets Corp., Lazard Ltd (NYSE:LAZ)


Most Recent Auditor
KPMG LLP - Klynveld Peat Marwick Goerdeler


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
CFRA Equity Research

Oct 08, 2023 04:29 AM
TH
Theratechnologies Inc.
Reports
9
CFRA Equity Research

Oct 08, 2023 03:04 AM
TH
Target Hospitality Corp.
Reports
9
S&P Global Compustat

Oct 05, 2023 03:31 AM
TH
Theratechnologies Inc 2023_10_05
Reports
14
Research Capital Corporation
Uddin, Andre
Oct 04, 2023 07:34 AM
TH
Egrifta MDV - Going On A Date With The FDA
Reports
8
GlobalData

Oct 04, 2023 01:30 AM
TH
Theratechnologies Inc (TH.TSE) - Financial and Strategic SWOT Analysis Review
Reports
237
ValuEngine, Inc.

Oct 02, 2023 07:22 AM
TH
ValuEngine - Toronto Quantitative Stock Report for TH
Reports
9
ValuEngine, Inc.

Oct 02, 2023 05:40 AM
TH
ValuEngine Rating and Forecast Report for THTX
Reports
11
Leede Jones Gable Inc
Loe, Douglas W.
Sep 27, 2023 07:45 AM
TH
LJG: Theratechnologies Inc. | TH-TSX - Update
Notes
8
National Bank Financial
Leno, Endri
Sep 26, 2023 03:20 PM
TH
Finding a Footing With Positive Adj. EBITDA
EPS Estimates*
7
Canaccord Genuity
Maughan, William Patrick
Sep 26, 2023 02:47 PM
TH
EBITDA-positivity encouraging, but we are watching for growth drivers to perform
EPS Estimates*
6


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Soleus Capital Management, L.P.

2,331,377

9.63

6.2

Jun-30-2023


Morgan Stanley, Investment Banking and Brokerage Investments

1,988,025

8.21

5.3

Jun-30-2023


Aigh Capital Management, LLC

851,177

3.52

2.3

Jun-30-2023


National Bank Investments Inc.

135,758

0.56

0.4

Jun-30-2023


Canadian Imperial Bank of Commerce, Asset Management Arm

104,397

0.43

0.3

Jun-30-2023


Cyndeo Wealth Partners, LLC

104,121

0.43

0.3

Jun-30-2023


Stifel Asset Management Corp.

89,559

0.37

0.2

Jun-30-2023


SagePoint Financial Advisors, Inc., Securities Investments

82,131

0.34

0.2

Jun-30-2023


Svoronos, Dawn A.

80,900

0.33

0.2

Apr-13-2023


Hamilton Capital, LLC

44,072

0.18

0.1

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Soleus Capital Management, L.P.
2,331,377
58,750
Morgan Stanley, Investment Banking and Brokerage Investments
1,988,025
23,150
Johnson Midwest Financial, LLC
8,000
6,250
National Bank Investments Inc.
135,758
6,125
SagePoint Financial Advisors, Inc., Securities Investments
82,131
2,500

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Thrivent Trust Company, Asset Management Arm
0
(26,625)
Millennium Management LLC
3,574
(9,709)
Two Sigma Securities, LLC, Asset Management Arm
13,471
(6,928)
Renaissance Technologies LLC
5,635
(5,665)
Littlejohn B.A., B.C.L., M.B.A., Gary 
0
(4,765)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
EGRIFTA, EGRIFTA SV, Licensing of EGRIFTA, Melanotransferrin Peptides (Future), Sudocetaxel Zendusortide (Future), TH-1904 (Future), TH1901 (Future), TH1902 (Future), Trogarzo


Upcoming Events
Date/Time
Type
Oct-12-2023
Estimated Earnings Release Date (S&P Global Derived)
Oct-16-2023
Company Conference Presentations
Oct-16-2023
Conferences
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Language
Size
Sep-26-2023
Sep-26-2023
Theratechnologies Inc. (TSX:TH)
SEC
6-K
English
118 KB
Sep-26-2023
Sep-26-2023
Theratechnologies Inc. (TSX:TH)
SEC
6-K
English
814 KB
Sep-26-2023
Aug-31-2023
Theratechnologies Inc. (TSX:TH)
SEDAR
Interim Financial Statements
English
755 KB
Sep-26-2023
Aug-31-2023
Theratechnologies Inc. (TSX:TH)
SEDAR
Interim Financial Statements
French
684 KB
Sep-25-2023
Sep-25-2023
Theratechnologies Inc. (TSX:TH)
SEC
6-K
English
26 KB
Sep-25-2023
-
Theratechnologies Inc. (TSX:TH)
SEDAR
Material Change Report
French
131 KB
Sep-25-2023
-
Theratechnologies Inc. (TSX:TH)
SEDAR
Material Change Report
English
81 KB
Sep-25-2023
-
Theratechnologies Inc. (TSX:TH)
SEDAR
Material Change Report
French
131 KB
Sep-25-2023
-
Theratechnologies Inc. (TSX:TH)
SEDAR
Material Change Report
English
81 KB
Sep-25-2023
-
Theratechnologies Inc. (TSX:TH)
SEDAR
Material Change Report
French
131 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Arena, Joseph P. (Independent Director)
Oct-21-2022
Common Shares
625
6,699
Open Market Acquisition
20.00
Multiple
Svoronos, Dawn A. (Independent Chair of the Board)
Oct-20-2022
Common Shares
12,500
0
Derivative Exercise and Retained Stock
18.27
Multiple
Lafond L.L.M., LL.B., Jocelyn  (General Counsel & Corporate Secretary)
Jul-19-2022 - Jul-21-2022
Common Shares
(5,000)
(30,616)
Derivative Exercise and Sale
-
Multiple
-
Jul-21-2022
Common Shares
(1,550)
(18,512)
Sale
-
Exchange Announcement
-
Jul-19-2022
Common Shares
5,000
8,015
Derivative Exercise
-
Exchange Announcement
-
Jul-19-2022
Common Shares
(1,750)
0
Sale
-
Exchange Announcement
-
Jul-21-2022
Common Shares
(200)
(2,397)
Sale
-
Exchange Announcement
-
Jul-21-2022
Common Shares
(750)
(9,021)
Sale
-
Exchange Announcement
-
Jul-19-2022
Common Shares
(750)
(8,701)
Sale
-
Exchange Announcement
Holler MBA, Frank A. (Independent Director)
May-03-2022
Common Shares
9,750
134,872
Open Market Acquisition
New
Multiple
Arena, Joseph P. (Independent Director)
May-02-2022
Common Shares
1,250
15,409
Open Market Acquisition
66.67
Multiple
-
May-02-2022
Common Shares
25
314
Open Market Acquisition
-
Exchange Announcement
-
May-02-2022
Common Shares
1,225
15,095
Open Market Acquisition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Svoronos, Dawn A.
Independent Chair of the Board
514 336 7800
514 331 9691

Lévesque, Paul 
President, CEO & Director
514 336 7800
514 331 9691

Lacoste, Gerald A.
Independent Director
514 336 7800
514 331 9691

MacCandlish-Weil, Dale 
Independent Director
514 336 7800
514 331 9691

Trudeau, Alain 
Independent Director
514 336 7800
514 331 9691

Arena, Joseph P.
Independent Director
514 336 7800
514 331 9691

Clemmons, David 
Member of the Scientific Advisory Board
514 336 7800
514 331 9691

Falutz, Julian
Member of the Scientific Advisory Board
514 336 7800
514 331 9691
-
Grinspoon, Steven
Member of the Scientific Advisory Board
514 336 7800
514 331 9691
-
Guillemin, Roger 
Member of the Scientific Advisory Board
514 336 7800
514 331 9691

Holler, Frank A.
Independent Director
604-688-6877 x12
514 331 9691
fholler@lionscapital.com
Merriam, George R.
Member of the Scientific Advisory Board
514 336 7800
514 331 9691
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Lévesque, Paul 
President, CEO & Director
514 336 7800
514 331 9691

Dubuc, Philippe 
Senior VP & CFO
+1-438-315-6608
514 331 9691

Lafond, Jocelyn 
General Counsel & Corporate Secretary
(438) 315-6607
514 331 9691

Dupras, Andre 
Vice President of Human Resources
514 336 7800
514 331 9691

Marsolais, Christian 
Senior VP & Chief Medical Officer
514 336 7800
514 331 9691

Leasure, John 
Global Commercial Officer
514 336 7800
514 331 9691

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
